Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension

Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Yuji Itabashi, Keiichi Fukuda, Masaharu Kataoka

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The evidence regarding triple oral combination therapy for patients with pulmonary arterial hypertension (PAH) is scarce. This study was performed to investigate the effectiveness and safety of triple oral combination therapy with macitentan, riociguat, and selexipag. Methods: Among consecutive patients with PAH who were referred to our hospital from 2009 to 2020, those who underwent triple oral combination therapy using macitentan, riociguat, and selexipag were retrospectively analyzed. Hemodynamic and echocardiographic assessments and Kaplan–Meier analyses of all-cause death and initiation of prostacyclin infusion were conducted. Results: Twenty-six patients underwent this combination therapy. These patients were predominantly female (73.1%) with a median age of 38 years at baseline and nine patients were taking some PAH medications at baseline. The median time from initiation of the first PAH drug to the third PAH drug in treatment naïve patients was 24 days (interquartile range, 12–47 days). Four patients (15.0%) discontinued taking any of the three vasodilators because of adverse events, and 17 patients (65.4%) reached the maximum dose of all three drugs. The mean pulmonary arterial pressure, pulmonary vascular resistance, and cardiac output improved by 29%, 65%, and 82%, respectively (median observation period: 441 days) and similar improvements were observed in treatment-naïve patients at baseline. The survival rate and prostacyclin infusion-free rate since administration of all three vasodilators was 93.3% and 74.6% at 3 years, respectively. When patients were divided by risk stratification, the prostacyclin-free rate at 3 years was 92.9% in low-/intermediate-risk patients and 55.0% in high-risk patients. Conclusion: Triple oral combination therapy with macitentan, riociguat, and selexipag sufficiently improved clinical parameters and was well tolerated in patients with PAH. This combination could be a particularly promising strategy in patients with low/intermediate risk and possibly even in half of patients with high risk. Further studies are needed to validate these findings. The reviews of this paper are available via the supplemental material section.

Original languageEnglish
JournalTherapeutic Advances in Respiratory Disease
Volume15
DOIs
Publication statusPublished - 2021

Keywords

  • prognosis
  • pulmonary arterial hypertension
  • right ventricular function
  • risk stratification
  • triple oral combination therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this